title: Recurrence risk of oculorespiratory syndrome after influenza vaccination: randomized controlled trial of previously affected persons.
abstract: BACKGROUND
  Oculorespiratory syndrome (ORS) after influenza vaccination has many features of an allergic reaction.
  
  
  METHODS
  The objective of the study was to estimate the recurrence rate of ORS after receipt of either of 2 influenza vaccines available in Canada for the 2002-2003 influenza season in individuals who experienced ORS in 2000 or 2001. We designed a randomized, crossover, double-blind, placebo-controlled trial in which patients received the vaccine and the placebo 7 days apart. Patients were contacted by telephone at 24 hours and seen at 7 days to collect information about the recurrence of ORS symptoms. The 146 patients belonged to 3 groups: group A (46 patients) had ORS in 2000 but were not revaccinated in 2001, group B (50 patients) had ORS in 2000 and were revaccinated in 2001, and group C (50 patients) had ORS in 2001 but not in 2000. Half of the participants received Fluviral S/F (Shire Biologics) and half received Vaxigrip (Aventis Pasteur). The main outcome measure was the risk difference in ORS symptoms in the 24 hours after receiving the vaccine and after receiving placebo.
  
  
  RESULTS
  Recurrence attributable to the vaccine occurred in 34% (95% confidence interval, 21%-47%) of patients after receiving Fluviral S/F and in 15% (95% confidence interval, 2%-28%) after receiving Vaxigrip. The rate was twice as high in group A vs groups B and C. The risk of ORS was highest and most significant in group A patients vaccinated with Fluviral S/F. Most cases were mild, with 94% of patients with recurrence indicating that they would still be revaccinated the next year.
  
  
  CONCLUSIONS
  Despite high recurrence rates, revaccination of persons previously affected by ORS seems to be safe. Oculorespiratory syndrome is not anaphylactic, and most recurrences are benign. Most patients remain willing to be revaccinated.
authors.affiliation: Institut National de Santé Publique du Québec, Québec, Canada. gaston.deserres@sss.gouv.qc.ca
authors.forename: Gaston
authors.initials: G
authors.lastname: De Serres
authors.forename: Danuta M
authors.initials: DM
authors.lastname: Skowronski
authors.forename: Maryse
authors.initials: M
authors.lastname: Guay
authors.forename: Louis
authors.initials: L
authors.lastname: Rochette
authors.forename: Karen
authors.initials: K
authors.lastname: Jacobsen
authors.forename: Theresa
authors.initials: T
authors.lastname: Fuller
authors.forename: Bernard
authors.initials: B
authors.lastname: Duval
mesh_terms: D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000368:Aged; D002170:Canada / Q000453:epidemiology; D018592:Cross-Over Studies; D015817:Eye Infections / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology*; D005260:Female; D006801:Humans; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000009:adverse effects*; D007251:Influenza, Human / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D011336:Probability; D012008:Recurrence; D012016:Reference Values; D012141:Respiratory Tract Infections / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology*; D018570:Risk Assessment; D012720:Severity of Illness Index; D017678:Sex Distribution; D013577:Syndrome; D014611:Vaccination / Q000009:adverse effects* / Q000379:methods
chemical_list: D007252:Influenza Vaccines